Delivery Order SPE2DB22D3501-SPE2DB25FUN10

Award Date 2/11/25
Potential Completion Date 2/12/25
Potential Value $1.2K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,358.34 firm fixed-price contract is for the supply of Daliresp 500 mcg tablets, with a performance period through December 1, 2023. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 with the DLA Troop Support Medical, which serves...
This federal contract award, valued at $2,862.64, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for the drug Daliresp 500 mcg Tablet 30s, with a period of performance through May 1, 2023. The contract is a firm fixed-price arrangement, with no set-aside designation indicated. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC)...
This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) Troop Support Medical. The $1,401.58 firm-fixed-price delivery order is for the supply of DALIRESP 500 MCG TABLET 90S, a pharmaceutical product. The contract has an ultimate completion date of January 16, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) for the delivery of DALIRESP 500 MCG TABLET 30S. The contract has a ceiling value of $6,911.38 and a completion date of January 16, 2025. It is a firm fixed-price delivery order contract, without any set-aside designation. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is for the delivery of DALIRESP 500 MCG tablets. The $2,931.41 fixed-price delivery order was issued by the Defense Logistics Agency (DLA), a defense agency, and has an ultimate completion date of December 19, 2024. This contract is not designated as a set-aside. The award is associated with a larger $999,999,999 Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop...
This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA) for the delivery of DALIRESP 500 MCG TABLET 90S. The contract has a ceiling value of $5,209.62 and runs through February 4, 2025. It is a Firm Fixed Price Delivery Order contract, with no set-aside designation indicated. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of DALIRESP 250 MCG TABLET UD 20S, with a total ceiling value of $3,443.05 and a period of performance through March 6, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026....
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $6,201.40 firm fixed-price delivery order supports the supply of DALIRESP 500 MCG TABLET 30S, a medical product, to the DLA. The award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical, which serves as a primary vehicle for...
This federal contract award, with ID SPE2DB20D2014|SPE2DB23FC11R, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $10,256.66 fixed-price delivery order is for the supply of DALIRESP 500 MCG TABLET 90S, a pharmaceutical product, with a performance period through May 3, 2023. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,115.40, is for the provision of DALIRESP 250 MCG TABLET UU 28S, a pharmaceutical product. This delivery order is part of a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA, valued at $999,999,999 and running through November...
  • SPE2DB22D3501
    Indefinite Delivery Contract
  • SPE2DB22D3501-SPE2DB25FUN10
    Delivery Order

This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,217.53, is a firm fixed-price delivery order to provide Daliresp 500 mcg tablets. The award has no set-aside designation, indicating open competition.

AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, covering similar medical products and prescription drugs. These IDCs enable efficient government procurement of essential pharmaceutical and medical supplies for military personnel, veterans, and other federal beneficiaries.

Generated 5/13/25, 10:00 AM